AbstractGet full access to this articleView all access options for this article.Get accessReferences1. Graham DJ . Telithromycin and acute liver failure. N Engl J Med 2006; 355:21:2260–1.2.FDA drug approval package: Ketek (telithromycin), 2004. www.fda.gov/cder/foi/nda/2004/21-144_Ketek.htm. (accessed 2007 Apr 15).3. Brophy JM . Selling safety: lessons from muraglitazar. JAMA 2005; 294:2633–5.4. Nissen SE , Wolski K , Topol EJ . Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005; 294:2581–6.5.FDA advisory committee briefing document: Pargluva (muraglitazar, BMS-298585), 2005. www.fda.gov/ohrms/dockets/ac/05/briefmg/2005-4169B2_02_00-FDATOC.htm (accessed 2007 May 9).
